Research programme: protease-activated monoclonal antibodies - CytomX Therapeutics

Drug Profile

Research programme: protease-activated monoclonal antibodies - CytomX Therapeutics

Alternative Names: CTX-023; CTX-033; CTX-1003; CX 188; CX 2005; EGFR Probody Drug Conjugate; J43 antibody; PD-1 probody therapeutic - CytomX Therapeutics; Probodies; Probody™ cancer therapeutics - Bristol-Myers Squibb

Latest Information Update: 13 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator CytomX Therapeutics
  • Developer Bristol-Myers Squibb; CytomX Therapeutics
  • Class Drug conjugates; Monoclonal antibodies
  • Mechanism of Action Cytotoxic T-lymphocyte antigen 4 inhibitors; Epidermal growth factor receptor antagonists; Immunomodulators; Notch signalling pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer
  • No development reported Autoimmune disorders
  • Discontinued Inflammation

Most Recent Events

  • 13 Nov 2017 CX 188 is still in preclinical development for Cancer in USA (Cytomx pipeline, November 2017)
  • 07 Nov 2017 CytomX plans to file an IND application with the US FDA of CX 188 in USA in the second half of 2018
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top